prohibit pharmaceutical manufacturers from interfering in contracts between 340B entities and pharmacies and to provide a penalty therefor.

This bill prohibits pharmaceutical manufacturers from interfering with contracts between 340B entities and pharmacies, directly affecting drug manufacturers and healthcare organizations that participate in the 340B drug pricing program. The legislation establishes penalties for manufacturers who attempt to influence these contractual relationships, aiming to protect the integrity of the program's pricing structure. By creating specific consequences for interference, the bill seeks to maintain the existing agreements between covered entities and their pharmacy partners without manufacturer obstruction.